Skip to main content
Fig. 6 | Arthritis Research & Therapy

Fig. 6

From: Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Fig. 6

Comparison of clinical efficacy variables between patients responding early or late to certolizumab pegol (CZP), and American College of Rheumatology (ACR)20 non-responders who re-consented to the open-label extension study. a Percentage of patients achieving clinical outcomes at week 232 for early or late responders and ACR20 non-responders. b Change from baseline in mean disease activity score in 28 joints (erythrocyte sedimentation rate) (DAS28(ESR)) score in ACR20 non-responders compared to CZP intention-to-treat (ITT). c Change from baseline in mean health-assessment questionnaire-disability index (HAQ-DI) score in ACR20 non-responders compared to CZP ITT (last observation carried forward). Response was defined by ACR20 response or decrease from baseline in DAS28(ESR) ≥1.2. Early responders were those who responded to CZP at week 12 and late responders were those who responded to CZP at week 24 but not at week 12. aRemission defined as DAS28(ESR) <2.6; blow disease activity (LDA) defined as DAS28(ESR) ≤3.2; cdefined as a decrease from baseline of ≥0.22 in HAQ-DI. MCID minimal clinically important difference

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us